Cost-Effectiveness of Vaccination against Invasive Pneumococcal Disease among People 50 through 64 Years of Age: Role of Comorbid Conditions and Race-Reference-Cited by-同舟云学术

Cost-Effectiveness of Vaccination against Invasive Pneumococcal Disease among People 50 through 64 Years of Age: Role of Comorbid Conditions and Race

Published:2003-06-17 Issue:12 Volume:138 Page:960
ISSN:0003-4819
Container-title:Annals of Internal Medicine
language:en
Short-container-title:Ann Intern Med

Author:

Sisk Jane E.¹,Whang William¹,Butler Jay C.¹,Sneller Vishnu-Priya¹,Whitney Cynthia G.¹

Affiliation:

1. From the Mount Sinai School of Medicine and Mailman School of Public Health, Columbia University, New York, New York; Massachusetts General Hospital, Boston, Massachusetts; and Centers for Disease Control and Prevention, Anchorage, Alaska, and Atlanta, Georgia.

Publisher

American College of Physicians

Subject

General Medicine,Internal Medicine

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Changes in the cost‐effectiveness of pneumococcal vaccination and of programs to increase its uptake in U.S. older adults;Journal of the American Geriatrics Society;2024-06

2. Pneumococcal Vaccination Strategies in 50-Year-Olds to Decrease Racial Disparities: A US Societal Perspective Cost-Effectiveness Analysis;Value in Health;2024-06

3. Cost-effectiveness analysis of adult pneumococcal conjugate vaccines for pneumococcal disease in Japan;Expert Review of Vaccines;2024-05-09

4. Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Argentinean Adults;Infectious Diseases and Therapy;2024-05-03

5. Nasal Staphylococcus aureus Carriage and Antimicrobial Resistance Profiles Among Community-Dwelling Adults in Jiangsu, China;Infectious Diseases and Therapy;2024-05-03